Neuroventi introduces autism treatment development pipeline at BIO KOREA 2022... "Conquering the only mental illness without a cure...

22-05-16

Neuroventi Co., Ltd. (CEO Shin Chan-young) participated in 'BIO KOREA 2022' held at COEX, Seoul from May 11 (Wed) to 13 (Fri).

Neuroventi is a new drug venture company that aims to realize a brain well-being society through the treatment of brain development disorders and intractable brain diseases and the utilization of optimal brain functions. It develops treatments for brain development disorders, including autism and ADHD, and has recently confirmed three or more candidates for autism treatment and is preparing for additional clinical trials.

Established in 2015, Neuroventi started at Konkuk University Medical Research Building, and as a result of research and development, it achieved certification as a venture company and achieved KRW 150 million in sales from natural product development efficacy search within one year of founding. It has also achieved significant results through research on the efficacy of drug development, and in recognition of this, last year it was awarded a commendation from the Health Industry Development Institute as an excellent company in health and medical technology.

At this exhibition, Neuroventi introduced drug candidate substances that are currently being researched and developed by the company. In particular, he emphasized the development of autism treatment through electronic medicine, explaining that the company's electronic medicine can cure autism patients' lack of sociality, communication problems, and repetitive behavior. He also emphasized that although it had high market potential, it is the only CNS disease for which no treatment has been developed, so global pharmaceutical companies are paying attention to it.

Neuroventi's autism treatment is being developed as a drug candidate for treatment based on accurate evidence and a complex action point treatment drug targeting various receptors and enzymes. As a result, it is possible to overcome the limitations of single-target treatments that have repeatedly failed, and it is expected to increase the probability of success in clinical trials.

An official from Neuroventi said, "Currently, we are in the process of establishing cooperative relationships with many domestic pharmaceutical companies specializing in drugs for neurological diseases, and we are aiming to attract Series B investment in the second half of 2022." We will imprint our name on various pharmaceutical companies and potential investors," he said, explaining the reason for participating in the exhibition.

"In addition, in the field of electronic medicine development, we have completed an agreement ceremony with a company that is actually conducting joint research, and clinical trials are currently underway," he said. As exchanges are taking place, we expect good results.”

Meanwhile, 'BIO KOREA 2022', which celebrated its 17th this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. BIO KOREA is solidifying its position as Korea's representative bio-health international convention, with world-renowned scholars and business experts participating every year. BIO KOREA 2022, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, will be held with various programs such as conferences, business forums, exhibitions, and invest fairs. it went on